目的:探討IVF-ET周期中,對常規IVF完全受精失敗的卵子補行卵胞漿內單精子注射精子(Rescue ICSI)的臨床應用價值。方法:在常規IVF后18～22 h,對體外受精完全失敗的12個周期、85個未受精MⅡ期卵行補行ICSI。以同時期進行ICSI的34個周期、226個MⅡ期卵為對照,比較ICSI結局。結果:補救ICSI組與對照組比較,基礎內分泌指標,HCG 日平均血清雌二醇和孕激素水平、子宮內膜厚度,獲MⅡ期卵個數以及平均移植胚胎個數,無顯著性差異。補救ICSI組受精率和卵裂率分別為78.82％、91.04％,與對照組(受精率為80.09%,卵裂率為95.58%)比較,差異無統計學意義。取卵后第3天,補救ICSI組卵裂球數≥5的優質胚胎比例占13.11％,低于對照ICSI組(73.99％),差異有顯著性 (Plt;0.05)。對照ICSI組妊娠率為38.24％,補救ICSI組無一例妊娠。結論:補行ICSI雖然可使常規IVF中未受精卵受精并獲得胚胎,但是所得胚胎的發育潛能差,妊娠率極低,臨床應用價值有限。
ObjectiveTo systematically review the efficacy and safety of CoQ10 for idiopathic oligoasthenoteratozoospermia (iOAT). MethodsWe searched databases including PubMed, EMbase, MEDLINE, The Cochrane Library, CBM, CNKI, VIP and WanFang Data from inception to May 31th 2016 for randomized controlled trials (RCTs) on CoQ10 in the treatment of iOAT. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. ResultsSeven RCTs involving 803 patients were included. The results of meta-analysis showed, compared with the control group, the CoQ10 group could significantly increase sperm concentration (MD=3.37, 95%CI 0.68 to 6.05, P=0.01), the number of A grade spermatozoa (MD=5.06, 95%CI 3.84 to 6.28, P < 0.000 01), the number of A+B grade spermatozoa (MD=7.72, 95%CI 4.19 to 11.26, P < 0.000 1), the rate of morphologically normal sperm (MD=1.89, 95%CI 0.63 to 3.16, P=0.003) and sperm coenzyme Q10 level (MD=40.02, 95%CI 24.73 to 55.31, P < 0.000 01), while not improve the levels of serum sex hormone (FSH: MD=–3.48, 95%CI –5.17 to –1.79, P < 0.000 1; LH: MD=–3.23, 95%CI –7.55 to 1.08, P=0.14; T: MD=0.45, 95%CI –3.31 to 4.20, P=0.82). No significant difference in adverse event was noted between two groups. ConclusionThe evidence suggests that CoQ10 as empiric medical therapy for iOAT with low non-serious adverse event associated, may improve sperm concentration and percent sperm motility. However, the strength of evidence is low due to high risk of bias of the included studies. More rigorous studies are needed to verify the above conclusion.
Objective To summarize current research status of sperm protein 17 (SP17) in breast cancer. Method Bysearching PubMed, Web of Science, CNKI, and Wanfang databases, the studies about expression and function of SP17 in the breast cancer were summarized. Results SP17 only expressed in the breast cancer tissue but not in the normal breast tissue. The result of the study showed that SP17 was only detected in the metastatic stage of tumor cells. The preclinical trails found that the breast cancer cells with SP17 positive expression could be killed by the specific T lymphocyte. Conclusions SP17 might be a potential target of immunotherapy of breast cancer, it might promote metastasis of cancer. More studies are needed to further explore its function in tumor development, thus accelerate its application in clinical practice.
目的：探討雌激素影響人精子頂體反應的可能機制。方法：應用異硫氰酸熒光素標記豌豆凝集素熒光染色法（FITC-PSA）分析精子頂體反應（AR）、以分光光度比色法測定頂體酶（ACE）活性。結果：17β-雌二醇（17β-E2）可促進精子發生AR，并增強精子頂體酶的活性；去除培養液中的Ca2+后，17β-E2不能誘導精子發生AR；PKC抑制劑能明顯降低17β-E2所誘導的AR；E2-BSA亦能夠促進精子發生AR，其作用與17β-E2無顯著差異。結論：雌激素對人精子頂體反應有一定的促進作用，增強精子頂體酶活性可能是其作用途徑之一，此過程涉及了胞外Ca2+、PKC及精子膜上的ER或雌激素結合位點的參與。